Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.

Chemistry (Weinheim an der Bergstrasse, Germany) - 10 Feb 2017

Wang Yao, Koay Yen Chin, McAlpine Shelli R

Abstract excerpt

The phenotypes produced when cells are treated with the heat shock protein 90 (Hsp90) inhibitors AUY922 or 17-AAG (classical inhibitors) are different to those produced when cells are knocked down with Hsp90α. Pull-down assays using classical inhibitors suggest that these molecules bind to multiple targets other than Hsp90. Classical inhibitors also induce similar protein markers as other anti-cancer therapies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to Gene Knockdown Techniques
Share to HCT116 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heat Shock Transcription Factors

Share to HSP70 Heat-Shock Proteins

Share to HSP90 Heat-Shock Proteins

Share to Isoxazoles

Share to Lactams, Macrocyclic

Source

Identifiers

PMID: 27862436
DOI: 10.1002/chem.201604807

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.PMID 27862436Read ↗

Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in CancerSemantic proximity Read ↗

N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes.Semantic proximity Read ↗

Heat shock protein 90Semantic proximity Read ↗

HSP90 and the cancer transcriptome: a comprehensive review of inhibitors and mechanistic insightsSemantic proximity Read ↗

Combining an Hsp70 inhibitor with either an N- or C-terminal Hsp90 inhibitor produces mechanistically distinct phenotypes.Semantic proximity Read ↗

C-terminal heat shock protein 90 modulators produce desirable oncogenic properties.Semantic proximity Read ↗

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Semantic proximity Read ↗

Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors.Semantic proximity Read ↗

Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics.Semantic proximity Read ↗

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protractionSemantic proximity Read ↗

HSP70 Inhibition by the Small-Molecule 2-Phenylethynesulfonamide Impairs Protein Clearance Pathways in Tumor CellsSemantic proximity Read ↗

Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.